fuboTV – the Leading Sports-First Virtual MVPD – Raises $15 Million Series B Investment Led by 21st Century Fox and Sky
fuboTV, the fastest-growing virtual MVPD in the U.S., has today announced that it has raised US$15 million in Series B funding. Led by significant investments from Sky and 21st Century Fox, the round will be used to grow the company’s expanding sports-first streaming video offering, develop new features and market the service to increase its subscriber base. As a result of the equity agreements, both Sky and 21st Century Fox will take board positions.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160309006521/en/
fuboTV provides subscribers with a premium, over-the-top bundle of sports TV channels, featuring hundreds of live soccer matches, club videos, series, documentaries and other English, Spanish and Portuguese content. Officially launched in January 2015, fuboTV has quickly become the second-largest virtual MVPD in the U.S., growing to more than 40,000 subscribers to date. Its customer base is strongly concentrated in millennial males who are not traditional MVPD customers, and is 30 percent Latin American.
The fuboTV service has in place distribution deals with TV channels that hold U.S. rights to major worldwide sporting events, including soccer matches from more than half of the leading international soccer leagues and tournaments, a primary driver of its first-year subscriber growth. These include Univision Networks, beIN SPORTS, GolTV and Benfica TV, as well as the recently announced addition of entertainment networks targeting millennials such as El Rey Network, Pivot and REVOLT. Neither 21st Century Fox nor Sky are currently licensing content to fuboTV, but both companies intend to work closely with fuboTV as it continues to grow.
Emma Lloyd, director of corporate development & strategic investments at Sky, commented: “We’re really excited to be investing in fuboTV. This investment will provide Sky with real insight and we look forward to working with the fuboTV team as they continue to explore new opportunities for growth.”
“We are very impressed by the fuboTV management team and the great progress they have made in a very short time,” said Ravi Ahuja, executive vice president, business operations and development for 21st Century Fox operating unit Fox Networks Group. “Ultimately, we believe streaming services like fuboTV will drive further innovation and be a win-win for consumers and programmers.”
Prior to fuboTV, the company’s founders David Gandler (CEO), Sung Ho Choi (CTO) and Alberto Horihuela (CMO) built a strong track record in the entertainment and digital media industries, most recently as executives at OTT video company DramaFever – which is being acquired by Warner Bros.
“The support from two of the most prominent media companies in the world strongly positions fuboTV to meet the demands of the quickly evolving sports rights ecosystem,” said Gandler. “Investment from 21st Century Fox, Sky and the prominent individuals and organizations part of this Series B round demonstrates our potential to become leaders among linear OTT services.”
Sky and 21st Century Fox each invested US$6 million of the total US$15 million Series B round, which also includes investments from DCM Ventures, Luminari Capital, LionTree Partners, Edgar Bronfman, Jr. (Managing Partner at Accretive LLC and former CEO and Chairman of Warner Music Group), Chris Silbermann (founding partner, ICM Partners) and David Stern (former NBA commissioner and member of the Basketball Hall of Fame). fuboTV’s Series A investors are listed below.
fuboTV is the fastest-growing virtual MVPD in the U.S., bundling sports TV networks with entertainment content that complements its core offering. Officially launched in January 2015, it is currently the second-largest service of its kind, and the top provider of live streaming soccer in the U.S. Bringing subscribers access to linear channels from a growing line-up of content partners, fuboTV is available on desktops via www.fubo.tv; on Amazon Fire TV and Fire TV Stick; Android phones and tablets; Apple TV; Chromecast; iPad; iPhone; Kindle Fire; Roku; and T-Mobile’s Binge On. The company has raised a total of $20.6 million in funding to date. fuboTV closed a $4 million Series A round in August 2015, led by DCM Ventures and including I2BF Digital, LionTree Partners, Luminari Capital and Univision Communications Inc., as well as seed investments from Anthony Vinciquerra, former CEO of Fox Networks Group, and Blake Krikorian, co-founder of Sling Media. In February 2016, the company closed a $15 million Series B round led by Sky and 21st Century Fox and including DCM Ventures, Luminari Capital, LionTree Partners, Edgar Bronfman, Jr. (Managing Partner at Accretive LLC and former CEO and Chairman of Warner Music Group), Chris Silbermann (founding partner, ICM Partners) and David Stern (former NBA commissioner and member of the Basketball Hall of Fame).
About 21st Century Fox
21st Century Fox is the world's premier portfolio of cable, broadcast, film, pay TV and satellite assets spanning six continents across the globe. Reaching more than 1.8 billion subscribers in approximately 50 local languages every day, 21st Century Fox is home to a global portfolio of cable and broadcasting networks and properties, including FOX, FX, FXX, FXM, FS1, Fox News Channel, Fox Business Network, FOX Sports, Fox Sports Network, National Geographic Channels, STAR India, 28 local television stations in the U.S. and more than 300 international channels; film studio Twentieth Century Fox Film; and television production studios Twentieth Century Fox Television and a 50% ownership interest in Endemol Shine Group. The Company also holds a 39.1% ownership interest in Sky, Europe’s leading entertainment company, which serves 21 million customers across five countries. For more information about 21st Century Fox, please visit www.21CF.com.
Sky is Europe's leading entertainment company, serving 21 million customers across five countries: UK, Ireland, Germany, Austria and Italy. We offer the best and broadest range of content, deliver market-leading customer service and use innovative new technology to give customers a better TV experience, whenever and wherever they choose.
Sky has annual revenues of over £11 billion and is Europe's leading investor in television content with a combined programming budget of £4.9 billion. The group employs 30,000 people and is listed on the London Stock Exchange (SKY).
For more information visit www.sky.com/corporate.
The Lippin Group/NY C
Matt Biscuiti, 212-986-7080
Euan Fordyce, 020 7032 3276
21 st Century Fox
Nathaniel Brown, 212-852-7746
The Lippin Group/L.A.
Kevin Broderick, 323-965-1990
Samantha Chau for LEWIS
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on
ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27 | Pressemelding
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi
Smiths Detection Hold Baggage Scanner Meets Highest Security Standards in EU23.3.2018 07:00 | Pressemelding
The Smiths Detection HI-SCAN 10080 XCT has achieved ECAC approval as a Standard 3.1 explosives detection system for hold baggage – the highest, defined security standard in the EU. This significant advance was made possible by using a dual-view, dual-energy line scanner with high resolution 3D Computed Tomography (CT) to deliver exceptional data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005050/en/ Smiths Detection HI-SCAN 10080 XCT (Graphic: Business Wire) This achievement gives airports currently upgrading to Standard 3 technology, the option to increase detection levels even further to 3.1; and any standard 3 systems already installed can be easily elevated to 3.1 via a software upgrade. The detection algorithms are interchangeable on a bag by bag basis depending on the destination and associated risk level. This offers additional flexibility and productivity. “With the capability to meet detection requirements